Sotera Health Company (SHC)
| Market Cap | 4.49B +39.8% |
| Revenue (ttm) | 1.16B +5.7% |
| Net Income | 77.95M +75.6% |
| EPS | 0.27 +72.2% |
| Shares Out | 285.16M |
| PE Ratio | 57.70 |
| Forward PE | 16.16 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,050,935 |
| Open | 15.60 |
| Previous Close | 15.58 |
| Day's Range | 15.60 - 15.86 |
| 52-Week Range | 10.68 - 19.85 |
| Beta | 1.88 |
| Analysts | Buy |
| Price Target | 20.33 (+29.24%) |
| Earnings Date | May 5, 2026 |
About SHC
Sotera Health Company provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment offers outsourced terminal sterilization and irradiation services using gamma irradiation, ethylene oxide processing, and electron beam irradiation technologies for medical devices, pharmaceutical, and food safety and advanced applications markets. The Nordion seg... [Read more]
Financial Performance
In 2025, Sotera Health Company's revenue was $1.16 billion, an increase of 5.74% compared to the previous year's $1.10 billion. Earnings were $77.95 million, an increase of 75.79%.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for SHC stock is "Buy." The 12-month stock price target is $20.33, which is an increase of 29.24% from the latest price.
News
Sotera Health Announces First-Quarter 2026 Earnings Release Date
CLEVELAND, April 21, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services f...
Sotera Health Company Transcript: 2026 KeyBanc Capital Markets Healthcare Forum
The forum highlighted strong 2025 results, with 5.2% organic revenue growth and margin expansion. 2026 guidance projects continued growth, supported by capacity investments and disciplined capital allocation. Regulatory changes and segment strategies were discussed, with a focus on long-term value creation.
Sotera Health Appoints Kenneth D. Krause to the Board of Directors
CLEVELAND, March 16, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company” or “Sotera Health”), a leading global provider of mission-critical end-to-end sterilization solutions, ...
Sotera Health Company Transcript: Barclays 28th Annual Global Healthcare Conference
Energy and supply chain risks are well managed with fixed contracts and no current constraints. Strong financial performance in 2025 is expected to continue in 2026, with robust demand for ethylene oxide sterilization and stable pricing. Regulatory and litigation challenges are being addressed proactively.
Sotera Health Announces Secondary Offering of Common Stock
CLEVELAND, March 04, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 25 million shares of its common...
Sotera Health Company Earnings Call Transcript: Q4 2025
Delivered 20th consecutive year of revenue growth in 2025, with strong margin expansion and cash flow. 2026 guidance calls for 5–6.5% revenue growth and further EBITDA improvement, supported by robust med tech demand and disciplined capital allocation.
Sotera Health Delivers 20th Consecutive Year of Revenue Growth and Provides 2026 Outlook
2025 net revenues increased 5.7% to $1.164 billion , compared to 2024, or 5.2% on a constant currency basis 2025 net income increased to $78 million or $0.27 per diluted share, compared to net income ...
Sotera Health Announces Fourth-Quarter and Full-Year 2025 Earnings Release Date
CLEVELAND, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services fo...
Sotera Health Appoints Richard Kyle to the Board of Directors
CLEVELAND, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services fo...
Sotera Health Company Transcript: 44th Annual J.P. Morgan Healthcare Conference
The company reported strong 2025 results, surpassing $1.16 billion in revenue and exceeding growth and margin targets. Strategic investments in capacity, regulatory readiness, and integrated services position it for continued growth, with robust demand across all business segments and favorable legal outcomes supporting long-term confidence.
Sotera Health to Showcase Continued Revenue Growth and Strategic Value Creation at 44th Annual J.P. Morgan Healthcare Conference
CLEVELAND, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, l...
Sotera Health to Present at the 44th Annual J.P. Morgan Healthcare Conference
CLEVELAND, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (NASDAQ: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, l...
Sotera Health Company Transcript: Piper Sandler 37th Annual Healthcare Conference
Consistent med tech volume growth and stable supply chains support strong pricing and multi-year contracts. Regulatory changes and capital investments are well-managed, with CapEx set to decline and leverage targeted at 2–3x by 2027. Cross-segment synergies and reduced litigation risk further strengthen the outlook.
Sotera Health Company Transcript: Jefferies London Healthcare Conference 2025
The conference highlighted robust, consistent growth driven by integrated sterilization and testing services, strategic capital investments, and a focus on high-growth healthcare markets. Ongoing capacity expansion, disciplined capital allocation, and targeted M&A support a positive outlook for 2025–2027.
Sotera Health Company Transcript: Wolfe Research Healthcare Conference 2025
Volume growth has rebounded, driven by core customers and new capacity investments, with regulatory modernization on track for 2026. Financial health is strong, M&A is a focus, and segment updates show recovery in testing and secure supply in materials. Litigation risks are being managed effectively.
Sotera Health Company Earnings Call Transcript: Q3 2025
Q3 2025 saw 9.1% revenue growth, double-digit adjusted EBITDA gains, and margin expansion, with strong Sterigenics and Nordion performance. Guidance for 2025 was raised, debt was reduced, and litigation developments were favorable.
Sotera Health Reports Strong Third-Quarter and Year-to-Date 2025 Results
Q3 2025 net revenues increased 9.1% to $311 million , or 8.0% on a constant currency basis ( 1) , compared to Q3 2024 Q3 2025 net income of $48 million, or $0.17 per diluted share, compared to net in...
Sotera Health Announces Third-Quarter 2025 Earnings Release Date
CLEVELAND, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services fo...
Sotera Health Company Earnings Call Transcript: Q2 2025
Q2 2025 saw 6.4% revenue and 9.8% adjusted EBITDA growth, prompting raised full-year guidance for revenue, EBITDA, and EPS. Sterigenics led with double-digit growth, Nelson Labs achieved margin expansion, and leverage improved, supported by strong cash flow and disciplined capital allocation.
Sotera Health Reports Strong Second-Quarter and First-Half 2025 Results
CLEVELAND, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, l...
Sotera Health Announces Second-Quarter 2025 Earnings Release Date
CLEVELAND, July 28, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services...
Trends Shaping Qatar's Infection Control Market 2025-2034: Featuring Sidra Medicine, BD, Condair, Sotera Health, Olympus, 3M
The Qatar infection control market is driven by automated and AI-powered sterilization systems. Rising hospital admissions, awareness of healthcare-associated infections, and advanced disinfection tec...
Sotera Health Company Transcript: Jefferies Global Healthcare Conference 2025
Strong 2025 outlook is supported by stabilized supply chains, disciplined pricing, and growth in pharma and bioprocessing. Regulatory changes are expected to benefit larger players, while capital allocation focuses on organic growth and free cash flow.
Sotera Health Company Earnings Call Transcript: Q1 2025
Q1 2025 saw solid constant currency growth in revenue and adjusted EBITDA, with all segments meeting or exceeding expectations. Guidance for 2025 was reaffirmed, with margin expansion and strong liquidity, while tariff and supply risks remain minimal.
Sotera Health Reports First-Quarter 2025 Results
CLEVELAND, May 01, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, la...